Page 112 - 《中国药房》2022年22期

[ 3 ] NAJAFIAN B，KARIMI-SARI H，KHOSRAVI M H，et randomized controlled trials[J]. Pulm Pharmacol Ther，
al. Comparison of efficacy and safety of two available 2015，34：46-54.
natural surfactants in Iran，Curosurf and Survanta in treat‐ [14] 张强强，李国庆，钟丽红. 固尔苏和珂立苏治疗新生儿呼
ment of neonatal respiratory distress syndrome：a rando- 吸窘迫综合征有效性和安全性的 Meta 分析[J]. 中国现
mized clinical trial[J]. Contemp Clin Trials Commun， 代医药杂志，2019，21（11）：11-19.
2016，3：55-59. [15] SEKAR K，FUENTES D，KRUKAS-HAMPEL M R，et
[ 4 ] MIRZARAHIMI M，BARAK M. Comparison efficacy of al. Health economics and outcomes of surfactant treat‐
Curosurf and Survanta in preterm infants with respiratory ments for respiratory distress syndrome among preterm
distress syndrome[J]. Pak J Pharm Sci，2018，31（2）： infants in US level Ⅲ/Ⅳ neonatal intensive care units[J].
469-472. J Pediatr Pharmacol Ther，2019，24（2）：117-127.
[ 5 ] 叶冬炜，王莉，刘叔文. 卫生技术评估在欧洲4国的应用 [16] BROWN S，HURREN J，SARTORI H. Poractant Alfa
及对我国的启示[J]. 中国药房，2022，33（1）：1-6. versus beractant for neonatal respiratory distress syndrome：
[ 6 ] 嵇承栋，朱琳懿，万悦竹，等. 国际卫生技术评估机构协 a retrospective cost analysis[J]. J Pediatr Pharmacol Ther，
作网卫生技术评估报告清单解读[J]. 中国循证医学杂 2018，23（5）：367-371.
志，2016，16（3）：369-372. [17] ZAYEK M M，EYAL F G，SMITH R C. Comparison of
[ 7 ] SHEA B J，REEVES B C，WELLS G，et al. AMSTAR 2：a the pharmacoeconomics of calfactant and poractant Alfa
critical appraisal tool for systematic reviews that include in surfactant replacement erapy[J]. J Pediatr Pharmacol
randomised or non-randomised studies of healthcare inter‐ Ther，2018，23（2）：146-151.
ventions，or both[J]. BMJ，2017，358：j4008. [18] GERDES J S，SEIBERLICH W，SIVIERI E M，et al. An
[ 8 ] CHAO Y，GROBELNA A. Curosurf（poractant Alfa）for open label comparison of calfactant and poractant Alfa
the treatment of infants at risk for or experiencing respira‐ administration traits and impact on neonatal intensive care
tory distress syndrome：a review of clinical effectiveness， unit resources[J]. J Pediatr Pharmacol Ther，2006，11（2）：
cost-effectiveness，and guidelines[EB/OL].（2018-09-18） 92-100.
[2022-02-28]. https：//www. semanticscholar. org/paper/Curo‐ [19] MARSH W，SMEEDING J，YORK J M，et al. A cost
surf-（poractant-alfa）-for-the-Treatment-of-At-A-Chao-Gro- minimization comparison of two surfactants-beractant and
belna/8740666cf271657e7e6ec1806589e6f9bd95ee0a. poractant Alfa：based upon prospectively designed，com‐
[ 9 ] SÁNCHEZ LUNA M，BACHER P，UNNEBRINK K，et parative clinical trial data[J]. J Pediatr Pharmacol Ther，
al. Beractant and poractant Alfa in premature neonates 2004，9（2）：117-125.
with respiratory distress syndrome：a systematic review of [20] 郭军，钟晶，李静晶. 珂立苏和固尔苏在早产呼吸窘迫综
real-world evidence studies and randomized controlled 合征患儿中通气治疗对患儿通气效果及治疗费用影响
trials[J]. J Perinatol，2020，40（8）：1121-1134. [J]. 首都食品与医药，2018，25（10）：30-31.
[10] FOLIGNO S，DE LUCA D. Porcine versus bovine surfac‐ [21] BAROUTIS G，KALEYIAS J，LIAROU T，et al. Com‐
tant therapy for RDS in preterm neonates：pragmatic meta- parison of three treatment regimens of natural surfactant
analysis and review of physiopathological plausibility of preparations in neonatal respiratory distress syndrome[J].
the effects on extra-pulmonary outcomes[J]. Respir Res， Eur J Pediatr，2003，162（7/8）：476-480.
2020，21（1）：8. [22] LEMYRE B，FUSCH C，SCHMÖLZER G M，et al. Porac‐
[11] TRIDENTE A，DE MARTINO L，DE LUCA D. Porcine tant Alfa versus bovine lipid extract surfactant for infants
vs bovine surfactant therapy for preterm neonates with 24+0 to 31+6 weeks gestational age：a randomized con‐
RDS：systematic review with biological plausibility and trolled trial[J]. PLoS One，2017，12（5）：e0175922.
pragmatic meta-analysis of respiratory outcomes[J]. [23] BEEN J V，ROURS I G，KORNELISSE R F，et al. Cho‐
Respir Res，2019，20（1）：28. rioamnionitis alters the response to surfactant in preterm
[12] SINGH N，HALLIDAY H L，STEVENS T P，et al. Com‐ infants[J]. J Pediatr，2010，156（1）：10-15.e1.
parison of animal-derived surfactants for the prevention [24] COGO P E，FACCO M，SIMONATO M，et al. Pharmaco‐
and treatment of respiratory distress syndrome in preterm kinetics and clinical predictors of surfactant redosing in
infants[J]. Cochrane Database Syst Rev，2015（12）： respiratory distress syndrome[J]. Intensive Care Med，
CD010249. 2011，37（3）：510-517.
[13] ZHANG L，CAO H Y，ZHAO S，et al. Effect of exo- （收稿日期：2022-03-31 修回日期：2022-10-08）
genous pulmonary surfactants on mortality rate in neonatal （编辑：陈 宏）
respiratory distress syndrome：a network meta-analysis of

· 2790 · China Pharmacy 2022 Vol. 33 No. 22 中国药房 2022年第33卷第22期